ARGX compared with ALNY: revenue, margins and what each company keeps, and the suppliers and customers both name

ARGXArgenx SE

Mkt capRevenueRevenue

ALNYAlnylam Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

ARGXArgenx SE

ALNYAlnylam Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ARGX: latest quarter not drawable.Method ›

Price

rebased to 0%

ARGX, solidALNY, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ARGX 3

ABBVAbbViecustomer

HALOHalozyme Therapeuticssupplier

—AgomAb Therapeuticsunlistedcustomer

Shared 0

No shared counterparties.

Only ALNY 14

BXBlackstonesupplier

REGNRegeneroncustomer

AAgilentsupplier

VEEVVeeva Systemssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

10 more · ALNY chain ›

ARGXArgenx SE

893.85▼−0.45%· post 895.00

Mkt cap$55.3BRevenue—Revenue—

ALNYAlnylam Pharmaceuticals, Inc.

164.89▼−5.24%· post 165.53

ClosedOct 30 '26

Mkt cap$22.1BRevenue$1.5BQ3 FY26Revenue$3.7BFY25

Compare

ClosedOct 30 '26

ARGXArgenx SE

ALNYAlnylam Pharmaceuticals, Inc.

893.85▼−0.45%post 895.00

Price

164.89▼−5.24%post 165.53

$55.3B

Mkt cap

$22.1B

—

Revenue

$1.5BQ3 FY26

—

Revenue

$3.7BFY25

ARGX893.85▼−0.45%vsALNY164.89▼−5.24%ClosedOct 30 '26